PL3268493T3 - Markery mrna oparte na krwi pełnej do przewidywania nowotworu złośliwego prostaty oraz sposoby ich wykrywania - Google Patents

Markery mrna oparte na krwi pełnej do przewidywania nowotworu złośliwego prostaty oraz sposoby ich wykrywania

Info

Publication number
PL3268493T3
PL3268493T3 PL16713202T PL16713202T PL3268493T3 PL 3268493 T3 PL3268493 T3 PL 3268493T3 PL 16713202 T PL16713202 T PL 16713202T PL 16713202 T PL16713202 T PL 16713202T PL 3268493 T3 PL3268493 T3 PL 3268493T3
Authority
PL
Poland
Prior art keywords
detecting
methods
same
prostate cancer
whole blood
Prior art date
Application number
PL16713202T
Other languages
English (en)
Inventor
Deborah Ricci
Michael Gormley
Shibu THOMAS
Yashoda RAJPUROHIT
Michael Schaffer
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PL3268493T3 publication Critical patent/PL3268493T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/16Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL16713202T 2015-03-12 2016-03-11 Markery mrna oparte na krwi pełnej do przewidywania nowotworu złośliwego prostaty oraz sposoby ich wykrywania PL3268493T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562132064P 2015-03-12 2015-03-12
EP16713202.6A EP3268493B1 (en) 2015-03-12 2016-03-11 Whole blood based mrna markers for predicting prostate cancer and methods of detecting the same
PCT/US2016/022004 WO2016145308A2 (en) 2015-03-12 2016-03-11 Whole blood based mrna markers for predicting prostate cancer and methods of detecting the same

Publications (1)

Publication Number Publication Date
PL3268493T3 true PL3268493T3 (pl) 2022-05-09

Family

ID=55642872

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16713202T PL3268493T3 (pl) 2015-03-12 2016-03-11 Markery mrna oparte na krwi pełnej do przewidywania nowotworu złośliwego prostaty oraz sposoby ich wykrywania

Country Status (20)

Country Link
US (1) US20160304962A1 (pl)
EP (1) EP3268493B1 (pl)
JP (1) JP2018507702A (pl)
KR (1) KR20170136525A (pl)
CN (1) CN107567502A (pl)
CA (1) CA2979226A1 (pl)
CY (1) CY1125020T1 (pl)
DK (1) DK3268493T3 (pl)
ES (1) ES2905163T3 (pl)
HR (1) HRP20220128T1 (pl)
HU (1) HUE058025T2 (pl)
IL (1) IL254119A0 (pl)
LT (1) LT3268493T (pl)
MA (1) MA45480A (pl)
PL (1) PL3268493T3 (pl)
PT (1) PT3268493T (pl)
RS (1) RS62972B1 (pl)
SI (1) SI3268493T1 (pl)
SM (1) SMT202200062T1 (pl)
WO (1) WO2016145308A2 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3274476B1 (en) 2015-03-25 2023-06-07 The General Hospital Corporation Digital analysis of circulating tumor cells in blood samples
EP3985127A1 (en) * 2016-10-27 2022-04-20 The General Hospital Corporation Digital analysis of blood samples to determine efficacy of cancer therapies for specific cancers
CN107338319A (zh) * 2017-08-25 2017-11-10 天津艾至恩医疗科技有限公司 一种核苷酸引物及预测前列腺癌去势术预后的基因多态性检测试剂盒
KR102526906B1 (ko) * 2019-04-05 2023-05-02 주식회사 제놉시 Cfdna를 이용한 유방암 진단방법
CN110760585B (zh) * 2019-11-07 2022-12-09 深圳市华启生物科技有限公司 前列腺癌生物标志物及其应用
CN111500728A (zh) * 2020-05-13 2020-08-07 无锡市申瑞生物制品有限公司 检测人ar-v7及ar基因表达的引物探针组合物、试剂盒及检测方法
CA3253049A1 (en) * 2022-05-12 2023-11-16 Veracyte, Inc. PROGNOSIS AND TREATMENT OF MOLECULAR SUBTYPES OF PROSTATIC CANCER
KR102730255B1 (ko) * 2022-08-12 2024-11-15 (주)맥시온 암 진단용 다중 바이오마커 및 이의 용도
WO2025213150A1 (en) * 2024-04-06 2025-10-09 Precede Biosciences, Inc. Methods, kits and systems for measuring psa and psma expression and methods for treating cancer based on same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2836128T3 (es) * 2008-04-16 2021-06-24 Univ Johns Hopkins Método para determinar variantes del receptor de andrógenos en cáncer de próstata
EP2885428B1 (en) * 2012-08-17 2017-05-03 Memorial Sloan-Kettering Cancer Center Gene expression profile associated with prostate cancer
KR102241063B1 (ko) * 2013-03-15 2021-04-16 얀센 파마슈티카 엔.브이. 예측성 바이오마커에 대한 검정법

Also Published As

Publication number Publication date
SI3268493T1 (sl) 2022-04-29
ES2905163T3 (es) 2022-04-07
EP3268493B1 (en) 2022-01-05
CY1125020T1 (el) 2023-03-24
CN107567502A (zh) 2018-01-09
WO2016145308A3 (en) 2016-10-13
MA45480A (fr) 2018-01-17
PT3268493T (pt) 2022-04-13
EP3268493A2 (en) 2018-01-17
HUE058025T2 (hu) 2022-06-28
IL254119A0 (en) 2017-10-31
LT3268493T (lt) 2022-03-10
US20160304962A1 (en) 2016-10-20
SMT202200062T1 (it) 2022-03-21
WO2016145308A2 (en) 2016-09-15
JP2018507702A (ja) 2018-03-22
HRP20220128T1 (hr) 2022-04-29
RS62972B1 (sr) 2022-03-31
DK3268493T3 (da) 2022-03-07
KR20170136525A (ko) 2017-12-11
CA2979226A1 (en) 2016-09-15

Similar Documents

Publication Publication Date Title
IL267302A (en) Epigenetic markers and methods and measures related to them for the detection and management of certain types of cancer
IL254119A0 (en) Blood-based mrna markers for prostate cancer prediction and methods for its detection
ZA201900856B (en) Systems and methods for enhanced detection and quantification of analytes
IL234462B (en) Methods and apparatuses for predicting risk of prostate cancer and prostate gland volume
IL253546A0 (en) Method and system for determining cancer status
GB201618485D0 (en) Method of detecting tumour recurrence
IL253756B (en) A panel of biomarkers for cancer detection
DK3179393T3 (da) Genexpressionsprofilalgoritme og -test til bestemmelse af prognosen for prostatakræft
PL3357000T3 (pl) Systemy i metody wykrywania raka
IL253710A0 (en) Biomarkers for pancreatic cancer, and kits and methods to detect them
EP3156483A4 (en) Prostate cancer detection kit or device, and detection method
IL253160A0 (en) Cancer markers and methods of using them
IL251440B (en) Methods and systems for identifying analytes
ZA201604370B (en) Prostate cancer gene profiles and methods of using the same
HK1220253A1 (zh) 诊断前列腺癌症的方法
GB201718352D0 (en) Devices and methods for detection of biomarkers
IL260301A (en) Compositions and methods for assessing the risk of cancer occurrence
GB201602210D0 (en) Detection of cancer
SG11201702076WA (en) Cancer evaluation method and cancer evaluation system
EP3191846A4 (en) Methods of detecting prostate cancer
GB201619808D0 (en) Biomarkers for the prognosis and diagnosis of cancer
SG10202103525UA (en) Cancer biomarkers and methods of use
PT3298165T (pt) Método e kit para diagnóstico de cancro colorretal
GB201416868D0 (en) Mass spectral analysis of urine and other bodily fluids for the detection of cancer biomarkers
EP3618856A4 (en) MULTI-INDICATION RNA-BASED ANTI-CANCER IMMUNOTHERAPY